HILE 2026Q3: Single-quarter revenue of 103 million yuan, up 158.09% year-on-year; Oral business revenue and profit both increased

Source: Hile Bio 2026 Third Quarter Report

Single-quarter revenue up 158.09% / Single-quarter net profit attributable to shareholders of the parent company up 391.75% / Goodwill RMB 564 million

DGN | On October 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. (hereinafter referred to as "*ST HILE") released its unaudited third-quarter 2026 report: single-quarter operating revenue of RMB 103 million, up 158.09% year-on-year and up 16.54% quarter-on-quarter; total profit of RMB 18.1058 million, up 146.71% year-on-year; net profit attributable to shareholders of the parent company of RMB 10.3014 million, up 391.75% year-on-year and up 101.29% quarter-on-quarter; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses of RMB 10.0086 million, up 897.39% year-on-year and up 66.94% quarter-on-quarter.

Cumulative operating revenue for the first three quarters was RMB 239 million, up 59.63% year-on-year; total profit was RMB 38.2807 million, down 12.87% year-on-year; net profit attributable to shareholders of the parent company was RMB 21.7551 million, up 7.01% year-on-year; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses for the first three quarters was RMB 20.4911 million, up 24.39% year-on-year.

In addition, the company stated that during the reporting period, both its Oral business and In Vitro Diagnostics (IVD) business achieved further stable development, with revenue and profit growing year-on-year and quarter-on-quarter.

Regarding dental terminal stores, in order to strengthen unified management, seven dental chain companies under the original "Jinboli" brand in Yangzhou, Yizheng, Changzhou, Liyang and other places (1 dental hospital and 6 dental clinics or outpatient departments) have completed the industrial and commercial change registration for brand renaming, renamed as the "Jinhaili Dental" series, and hereinafter collectively referred to as "Jinhaili Dental".

Hunan Zeldon New Materials, a second-tier subsidiary, in order to strengthen the management of its foreign trade business, increased its shareholding ratio in its foreign trade business subsidiary Changsha Zeldon Biotechnology from 51% to 82%, and completed the industrial and commercial change registration on September 30, 2026.

Source: Hile Bio 2026 Third Quarter Report

Operating cost for the first three quarters was RMB 87.9303 million, up 126.77% year-on-year, higher than the 59.63% growth rate of operating revenue; calculated based on financial report data, the Gross Margin was 63.21%, compared with 74.11% in the same period last year, a decrease of 10.89 percentage points.

Selling expenses increased 77.11% year-on-year to RMB 47.1538 million, administrative expenses increased 23.48% year-on-year to RMB 36.4738 million, and R&D expenses increased 15.59% year-on-year to RMB 19.7901 million.

Source: Hile Bio 2026 Third Quarter Report

As of September 30, 2026, goodwill was RMB 564 million, an increase of RMB 182 million from RMB 382 million at the end of 2025. Cash and cash equivalents were RMB 124 million, down 41.95% from the end of 2025; Accounts Receivable were RMB 146 million, up 45.14%; Inventory was RMB 110 million, up 84.59%; total liabilities were RMB 363 million, up 58.55%.

Net Operating Cash Flow for the first three quarters was RMB 26.7286 million, down 27.31% year-on-year; net cash paid for acquisition of subsidiaries and other business units was RMB 175 million, compared with RMB 21.5071 million in the same period last year; net cash flow from investing activities was -RMB 137 million, and net cash flow from financing activities was RMB 26.3733 million, of which cash received from borrowings was RMB 85.00 million.